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Abstract
Purpose This prospective study evaluated the use of vascular, extracellular and restricted diffusion for cytometry in tumours
(VERDICT) MRI to investigate the tissue microstructure in glioma. VERDICT-derived parameters were correlated with both
histological features and tumour subtype and were also used to explore the peritumoural region.
Methods Fourteen consecutive treatment-naïve patients (43.5 years ± 15.1 years, six males, eight females) with suspected glioma
underwent diffusion-weighted imaging including VERDICT modelling. Tumour cell radius and intracellular and combined
extracellular/vascular volumes were estimated using a framework based on linearisation and convex optimisation. An experienced
neuroradiologist outlined the peritumoural oedema, enhancing tumour and necrosis on T2-weighted imaging and contrast-enhanced
T1-weighted imaging. The same regions of interest were applied to the co-registeredVERDICTmaps to calculate themicrostructure
parameters. Pathology sections were analysed with semi-automated software to measure cellularity and cell size.
Results VERDICT parameters were successfully calculated in all patients. The imaging-derived results showed a larger intra-
cellular volume fraction in high-grade glioma compared to low-grade glioma (0.13 ± 0.07 vs. 0.08 ± 0.02, respectively; p = 0.05)
and a trend towards a smaller extracellular/vascular volume fraction (0.88 ± 0.07 vs. 0.92 ± 0.04, respectively; p = 0.10). The
conventional apparent diffusion coefficient was higher in low-grade gliomas compared to high-grade gliomas, but this difference
was not statistically significant (1.22 ± 0.13 × 10−3 mm2/s vs. 0.98 ± 0.38 × 10−3 mm2/s, respectively; p = 0.18).
Conclusion This feasibility study demonstrated that VERDICT MRI can be used to explore the tissue microstructure of glioma
using an abbreviated protocol. The VERDICT parameters of tissue structure correlated with those derived on histology. The
method shows promise as a potential test for diagnostic stratification and treatment response monitoring in the future.
Key Points
• VERDICT MRI is an advanced diffusion technique which has been correlated with histopathological findings obtained at
surgery from patients with glioma in this study.
• The intracellular volume fraction measured with VERDICTwas larger in high-grade tumours compared to that in low-grade
tumours.
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• The results were complementary to measurements from conventional diffusion-weighted imaging, and the technique could be
performed in a clinically feasible timescale.
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Abbreviations
ADC Apparent diffusion coefficient
DWI Diffusion-weighted imaging
HGG High-grade glioma
IDH1 Isocitrate dehydrogenase 1
LGG Low-grade glioma
MRI Magnetic resonance imaging
T1W T1-weighted
T2W T2-weighted
VERDICT Vascular, extracellular and restricted diffusion
for cytometry in tumours
Introduction
Gliomas are primary brain tumours characterised by dif-
fuse infiltration and a poor prognosis [1, 2]. Genetic het-
erogeneity and phenotypic heterogeneity contribute to both
poor therapy response and tumour recurrence [3, 4].
Magnetic resonance imaging (MRI) is the imaging modal-
ity of choice but is limited in assessing tumour subtypes
and intratumoural heterogeneity [5–8]. In addition, con-
ventional imaging is ineffective in evaluating the spread
of tumour into the peritumoural region which may lead to
sub-optimal resection and recurrence [9]. Consequently,
new imaging biomarkers are required to improve the as-
sessment of glioma.
Several studies have addressed the importance of
diffusion-weighted imaging (DWI) and the apparent diffu-
sion coefficient (ADC) in evaluating gliomas but have
shown a partial overlap in the measured values between
subtypes [10–12]. The ADC may have a role in differen-
tiating high-grade glioma from metastases and in assessing
peritumoural oedema, but it cannot accurately differentiate
primary brain tumour subtypes [11–15]. The vascular, ex-
tracellular and restricted diffusion for cytometry in tu-
mours (VERDICT) is a model that infers tissue micro-
structure from DWI measurements [16]. This model de-
rives multiple compartments (intracellular, intravascular
and extracellular–extravascular spaces), has been applied
to xenograft models of colorectal cancer and to patient
studies of prostate cancer and has recently been shown to
be feasible in glioma [16–19]. Here, we have applied this
method to image intratumoural and intertumoural hetero-
geneity in glioma and validated with histology as part of a
prospective study.
Methods and materials
Patient selection
Fourteen consecutive treatment-naïve patients (six men, eight
women; age 43.5 years ± 15.1 years) were recruited into this
prospective ethically approved study from a neuro-oncology
multidisciplinary teammeeting or clinic. Subjects were sched-
uled for stereotactic biopsy or resection and gave written in-
formed consent.
MRI acquisition
MRI examinations were performed using a 3.0-T clinical
scanner and a 12-channel head coil (Discovery MR750; GE
Healthcare). Imaging included the following: 3D T2-weighted
(T2W) imaging (repetition time/echo time (TR/TE) 2500/
79 ms; 248 slices; slice thickness 1.2 mm; acquisition matrix
320 × 320; field of view (FOV) 240 mm× 240 mm), 2D T2W
fluid-attenuated inversion recovery (FLAIR) (TR/TE 8000/
126 ms; inversion time (TI) 2128 ms; slice thickness 6 mm;
acquisition matrix 384 × 224; FOV 240 mm× 240 mm) and
DWI (TR/TE 2841–3867/83.3–87.4 ms; slice thickness
5 mm; b value 0 and 1000 s/mm2; matrix 128 × 128; FOV
240 mm × 240 mm). Three-dimensional T1-weighted fast
spoiled gradient echo (T1W FSPGR) (252 slices; 0.94 mm×
0.94 mm× 1.5 mm reconstructed to 0.94 mm× 0.94 mm×
1 mm; TR/TE 8.2/3.2; slice thickness 1.5 mm; matrix 256 ×
256; FOV 240 mm× 240 mm) was performed before and after
gadolinium-based contrast injection (gadobutrol 1.0 mmol/mL;
Schering). ADC maps were generated as per clinical
standard.
VERDICT acquisition and post-processing
The parameters for DWI and VERDICT modelling are shown
in Table 1, and the spatial resolution was 2 mm isotropic [17].
For each b value, a separate b = 0 image was acquired to
compensate for varying T2-weighted imaging. To assess the
robustness of the five-b value–abbreviated acquisition, an ex-
tended protocol using 40 b values was undertaken in one
patient within the limits of the clinical gradient system
(Gmax, 45 mT/m; slew rate, 200 mT/m/s).
The tumours were located on T2W, and then 16 axial DWI
slices were acquired over the region of interest (ROI) for
VERDICT modelling. The acquisition time for each b value
was 66 s, with a total time of 330 s. Tumour cell radius,
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intracellular (IC) and combined extracellular (EC)/vascular
volume were calculated (Matlab 2016b, the MathWorks)
using a framework based on linearisation and convex optimi-
sation which provides an acceleration factor of 1500 [20, 21].
Intracellular and extracellular spaces were modelled separate-
ly, and therefore, the sum of both compartments was only
approximately 100%. Parameter maps were registered to
post-contrast 3D T1W and 3D T2W sequences (SPM12,
UCL).
MRI analysis
A neuroradiologist with 6 years of experience in neuro-
imaging outlined ROIs on axial T2W and axial 3D T1W
post-contrast sequences using OsiriX (V.8.5.2, Pixmeo
SARL). To assess the reproducibility of the ROI definition, a
second observer with 3 years of experience in neuro-imaging,
blind to the clinical data, performed a second analysis using
the same software. ROIs were drawn around the entire lesion
including the surrounding oedema using a combined evalua-
tion of T1W and T2W imaging. The 3D T1W post-contrast
images were used to better define the enhancing tissue and the
necrosis (if present) whilst the T2W images were used to bet-
ter highlight the oedema boundaries. ADC and VERDICT
maps were co-registered to the anatomical imaging to calcu-
late the microstructural parameters.
Pathological analysis
Histopathology was used to determine the tumour grade and
type using the WHO 2016 classification [1]. A neuropatholo-
gist with 7 years of experience evaluated tumour photomicro-
graphs from a × 600 FOV and a fixed matrix of 184 μm×
138 μm to assess cellularity and cell size using semi-
automated software (Image-Pro Insight). Average tumour cell
size was assessed by measuring the short and long axes of 20
cancer cells in each FOV. To determine if shrinkage post-
fixation affected these measurements, red blood cell size was
compared between a blood smear and a stained section in the
same patient [22, 23].
Statistical analysis
Statistical analysis was performed using a mathematical ana-
lytical software program (Matlab Statistics and Machine
Learning Toolbox, Matlab 2017a, MathWorks). The
Kolmogorov–Smirnov test was used to test for normality of
data. Comparisons between pathological analysis and
VERDICT parameters were performed using the Wilcoxon
rank-sum test. The same non-parametric statistical test was
used to assess the difference in cell size and density and to
compare the results obtained by the two observers. A statisti-
cal significance of a p value ≤ 0.05 was used. The Dice sim-
ilarity coefficient (DSC) was used to assess the reproducibility
of the segmentation performed by the two observers [24]; a
coefficient > 0.70 indicates a good overlap between the ROIs
[25, 26].
Results
The demographics and tumour characteristics are shown in
Table 2. VERDICT fitting was successfully performed for
all patients. The time window between imaging and surgery
was 17.5 ± 12.3 (median ± SD; range 4–46) days in patients
with low-grade glioma (LGG) and 5.2 ± 6.4 (1–17) days in
patients with high-grade glioma (HGG). The following pa-
tients were included: seven with LGG (four diffuse, isocitrate
dehydrogenase 1 (IDH1) R132H mutant astrocytomas; three
IDH1 R132H mutant, 1p19q co-deleted oligodendrogliomas)
and seven with HGG (six IDH wild-type glioblastomas; one
IDH wild-type astrocytoma).
Histopathological analysis
The histopathological measure of cell radius (Fig. 1) was not
significantly different in HGG compared to LGG (5.7 ±
1.4 μm (range 4.5–8.1) vs. 4.6 ± 1.6 μm (3.1–8.1), respective-
ly (p = 0.16)). The red blood cell size was 5.5 ± 0.7 μm (range
4.4–6.9) on fixed sections and 7.6 ± 0.6 μm (6.6–8) on the cell
smear (p < 0.001), demonstrating a reduction in size following
fixation.
Table 1 Diffusion MRI
parameters for the abbreviated
VERDICT model
b value
(s/mm2)
Δ/∂ (ms) Echo time (ms) |G| (mT/m) Number
of averages
Acceleration
factor
Full readout
bandwidth (Hz)
90 23.5/4.7 49.3 49.4 8 2 200,000
500 31.3/12.2 64.3 41.5 8 2 200,000
1500 43.4/25.8 91.4 30.1 8 2 200,000
2000 32.1/16.5 72.7 75.8 8 2 200,000
3000 43.8/24.8 89.4 43.9 8 2 200,000
The following are the parameters used for the shortened protocol: Δ is the time separation between the gradient
pulses, ∂ is the duration of the pulses and |G| is the combined gradient strength of the diffusion encoding
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There was a trend towards a higher histological cell density
in HGG compared to LGG (104 ± 43 cells/FOV (range 67–
170) vs. 51 ± 66.4 cells/FOV (35–210), respectively); the dif-
ference was not significant (p = 0.21).
VERDICT analysis
VERDICT parametric maps for LGG and HGG are shown in
Fig. 2. The calculated cell radius was similar in both groups
(6.8 ± 2.3 μm for HGG (range 4.3–11) and 6.7 ± 1.2 μm for
LGG (4.8–7.8); Fig. 1). There were no significant differences
between VERDICT radius measurements and those from
pathological sections for either LGG (p = 0.09) or HGG (p =
0.80). The intracellular volume fraction was higher in HGG
compared to LGG (0.13 ± 0.07 (range 0.08–0.27) vs. 0.08 ±
0.02 (0.07–0.14), respectively; p = 0.05). The extracellular/
vascular volume fraction showed the opposite trend with a
higher EC volume fraction in LGG compared to HGG, but
this was not significant (0.92 ± 0.04 (range 0.85–0.95) vs.
0.88 ± 0.07 (0.75–0.92), respectively; p = 0.10; Fig. 3). DWI
as per clinical standard was obtained in 12/15 patients. The
conventional ADC was higher in LGG compared to HGG
(1.22 ± 0.13 × 10−3 mm2/s (range 1.13–1.44) vs. 0.98 ±
0.38 × 10−3 mm2/s (0.77–1.74)); however, the difference was
not statistically significant (p = 0.18; Fig. 4).
Reproducibility analysis
The assessment of the reproducibility in the ROI segmentation
for the entire tumour region performed by the two observers
resulted in high reproducibility demonstrated by a DSC of
0.89 ± 0.06 (0.80–0.99). A sub-analysis performed according
to grading demonstrated similar results with a DSC of 0.89 ±
0.05 (0.82–0.94) for LGG and 0.89 ± 0.08 (0.80–0.99) for
HGG.
The results of the analysis performed by the second observ-
er are shown in Table 3.
Discussion
VERDICT is an advanced diffusion method which has previ-
ously been applied to pre-clinical models of cancer showing
microstructural differences between tumours and a decrease in
cell volume following chemotherapy [16]. The method has
also been shown to differentiate benign prostate tissue from
tumour in patients [17]. In this study, we have compared
VERDICT to histopathological findings at surgery and corre-
lated with tumour grade. Non-invasive grading of glioma is a
major challenge for conventional MRI, and biopsied tissue is
limited by sampling error as the tumour is very heterogeneous
[9]. Conventional ADC has a sensitivity and specificity for
differentiating high- and low-grade tumours of only 85%
and 80%, respectively, and there is a large overlap in ADC
between grades [27]. Therefore, additional imaging methods
Table 2 Demographic data and
histopathological characteristics
for high-grade and low-grade
tumours
Low-grade glioma High-grade glioma p
Age in years 33.2 ± 9.2 (24–45) 55.3 ± 11.9 (44–78) < 0.01
Men, n (%) 2 (28.6) 4 (57.1) 0.59
Lesion size in mm 44.4 ± 19.1 (23.1–68.7) 27.1 ± 17.2 (6.4–56.4) 0.13
IDH1 R132Ha, n (%)
Present 7 (100) 0 (0) < 0.01
Absent 0 (0) 7 (100)
MIB-1 (a.u.) 4.2 ± 3.0 (1–8.8) 19.2 ± 6.7 (12–31) < 0.001
The monoclonal antibody MIB-1 was used to determine the Ki-67 labelling index as a marker of proliferation.
Continuous values are expressed as mean ± SD with range in parentheses
aMutations involving isocitrate dehydrogenase 1
Fig. 1 a Box and whisker plot illustrating the cell radius as measured by
VERDICT MRI and pathology for low-grade glioma (LGG) and high-
grade glioma (HGG). bH&E staining from a low-grade glioma shown in
Fig. 2. c H&E staining from a high-grade glioma also shown in Fig. 2
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are required to accurately differentiate tumour subtypes and to
demonstrate tumour heterogeneity [12].
VERDICT parameters showed a higher intracellular vol-
ume fraction in HGG compared to LGG and a trend towards a
smaller extracellular/vascular volume fraction. As IC and EC
volume fractions are independently derived, their complemen-
tarity demonstrates intramodel consistency. Moreover, these
results were validated with the histological findings where
Fig. 2 a–f Representative images from a low-grade glioma. aAxial post-
gadolinium 3D T1-weighted imaging (T1WI). b Intracellular volume
fraction. c Cell radius maps. d Axial T2WI. e Extracellular volume frac-
tion. f ADC map, with a scale of × 10−6 mm2/s. Colour maps for b, c, e
have been superimposed on the greyscale image from a with the colour
scale shown for each image. g–lRepresentative images from a high-grade
glioma. g Axial post-gadolinium 3D T1WI. h Intracellular volume frac-
tion. i Cell radius maps. j Axial T2WI. k Extracellular volume fraction. l
ADC map, with a scale of × 10−6 mm2/s. Colour maps for h, i, k have
been superimposed on the greyscale image from a with the colour scale
shown for each image
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there was a higher cell density in HGGs compared to LGGs.
Importantly, although the conventional ADC was higher in
LGG compared to HGG, this was not statistically significant.
Therefore, VERDICT could provide important additional in-
formation which is complementary to conventional DWI.
VERDICT-derived maps showed a higher degree of hetero-
geneity compared to the corresponding ADC maps. This phe-
nomenon was particularly evident in HGG (Fig. 4) where re-
gional differences in the VERDICT maps were not visible on
ADC. The areas of high IC volume largely corresponded to the
independently derived areas of low EC volume, which again
provides evidence that the model is internally consistent.
Future studies can validate this heterogeneity using multire-
gional biopsies, and the technique could be used as a tool to
assess changes in this heterogeneity with treatment as well as a
method to assess the resection cavity following surgery [16].
The range of cell size was larger for HGG compared to
LGG on both VERDICT and histopathology in keeping with
the more heterogeneous nature of the higher-grade tumours.
The slight reduction in cell size measurements on histopathol-
ogy compared to the in vivo measurements may be accounted
for by shrinkage following fixation [22, 23]. Despite the cor-
relation between overall cell size on imaging and histology,
the patient-by-patient validation against pathology demon-
strated no statistically significant difference which may be
accounted for by sampling error, given that only a small pro-
portion of the tumour was biopsied and this may not represent
the whole tumour [16].
Rapid acquisition and data analysis are necessary for clini-
cal translation of the method, and the abbreviated VERDICT
MRI protocol proposed by Panagiotaki et al [28] was per-
formed here in 5.5 min, representing a reduction of 45 min
compared to the extended protocol. In addition, the data fitting
was combined with a post-processing algorithm based on
linearisation and convex optimisation which reduced the com-
puting bymore than 1500-fold to allow the analysis to bemade
available within a clinically applicable timescale (25.5 min ±
5.3 min) for acquisition and post-processing [20, 21].
The primary objective of the work was to assess the feasi-
bility of using VERDICTMRI to investigate the tissue micro-
structure in glioma in a clinical setting. The limitations of the
study include a small sample size which may have reduced the
statistical power of the study. Also, the original VERDICT
model is designed to compute the intracellular, intravascular
and extracellular–extravascular spaces in an animal model of
prostate cancer at a pre-clinical field strength of 9.4 T which
has significantly higher diffusion gradient capabilities of
~ 300 mT/m. The computational modelling can become unsta-
ble with the noise and time constraints experienced at clinical
field strength which can compromise the computational fit of
the intravascular compartment [17]. The correlation between
histology and imaging is also challenging as 2-mm-thick im-
aging slices were compared to 4-μm pathological slides which
could introduce sampling errors, particularly given the hetero-
geneous nature of glioma. Future larger studies are needed to
more fully validate the technique against histopathology and to
explore its potential applications as a routine clinical tool.
Fig. 3 Box and whisker plot showing intracellular (IC) volume fraction
and extracellular (EC) volume fraction for both low-grade glioma (LGG)
and high-grade glioma (HGG) derived from the VERDICT MRI model
Fig. 4 Apparent diffusion coefficient (ADC) values for low-grade glioma
(LGG) and high-grade glioma (HGG) as derived from conventional DWI
Table 3 Comparison between the
two observers LGG HGG
Obs 1 Obs 2 p Obs 1 Obs 2 p
Cell radius (μm) 6.7 ± 1.2 6.7 ± 1.5 0.53 6.8 ± 2.3 6.1 ± 2.1 1
IC volume fraction 0.08 ± 0.02 0.11 ± 0.03 0.07 0.13 ± 0.07 0.12 ± 0.06 0.93
EC volume fraction 0.92 ± 0.04 0.91 ± 0.05 0.60 0.88 ± 0.07 0.89 ± 0.05 0.94
Obs observer
The comparison between the VERDICT parameters derived by the analysis performed by the two observers.
Values are expressed as median ± SD
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In conclusion, VERDICT MRI could be a promising tech-
nique to assess the tissue microenvironment within glioma
using a clinically applicable protocol. The derived parameters
demonstrated larger cells and a trend towards a smaller extra-
cellular space in high-grade tumours compared to low-grade
tumours. This approach may provide additional information
compared to conventional diffusion-weighted imaging.
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